

Evaluation of Hepcidin in Pediatric Patients with Nephrotic Syndrome

**Thesis submitted for the partial fulfillment of
Master Degree in Pediatrics**

By

Dr. Eman Abd El Rahman El Sayed
(M.B. B. Ch., 2002, Al Azhar University)

Under Supervision of

Dr. Ihab Zaki Fouad El Hakim

Professor of pediatrics
Faculty of Medicine – Ain Shams University

Dr. Ahmed Abdullah Mohammed

Assistant Professor of pediatrics
Faculty of Medicine – Ain Shams University

Dr. Manal Mohammed Abd Al Aziz

Professor of clinical pathology
Faculty of Medicine – Ain Shams University

Faculty of Medicine

Ain Shams University

2010



Acknowledgement

All thanks to Allah the greatest of all for helping me to complete this work.

*I would like to express my sincere and deep gratitude to **Prof. Dr. Ihab Zaki Fouad El Hakim**, Professor of Pediatrics, and pediatric nephrology, Faculty of Medicine, Ain Shams University, for giving me the privilege of supervising this thesis and for his constructive encouragement, illuminating guidance as well as his support throughout this work.*

*I am really very grateful and deeply indebted to **Dr. Ahmed Abdullah Mohammad**, Assistant Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for his unfailing help, valuable suggestions and good support which helped me to put this work in its best form.*

I really wish to express my deep gratitude to

***Dr. Manal Mohammed Abd AlAziz**, Professor of clinical pathology Faculty of Medicine, Ain Shams University, for her kind assistance, precious and effective effort.*

*Lastly but not least, I would like to thank **all members** in my family for grate help pushing me forward all the time.*

List of the contents

	Page
List of figures	I-II
List of tables	III-V
List of abbreviations	VI-IX
Introduction and Aim of the work	1
Review of literature	4-57
Nephrotic syndrome	4
Hepcidin	33
Subjects and Methods	58
Results	64
Discussion	106
Conclusion	113
Recommendations	115
Summary	116
References	120
Arabic summary	_____

LIST OF ABBREVIATIONS

AA	Amino acid
ACEI	Angiotensin converting enzyme inhibitors
BMP	Bone morphogenetic proteins
C/EBP	Core element binding protein
CKD	Chronic kidney disease
CsA	Cyclosporine A
CYP	Cyclophosphamide
DBP	Diastolic blood pressure
EDTA	Ethylene diamine Tetra-acetic Acid
ELISA	Enzyme linked immunosorbent assay
ESA	Erythropoiesis stimulating agents
FRNS	Frequent relapses nephrotic syndrome
FSGS	Focal segmental glomerulosclerosis
GDF15	Growth differentiation factor-15
HAMP	Hepcidin antimicrobial peptide
HCT	Hematocrite

HD	Haemodialysis
HDL	High density lipoproteins
HFP	Hemochromatosis protein
HH	Hemochromatosis
HIF/vHL	Hypoxia inducible factor/von Hippel-Lindau
HTN	Hypertension
IL-6	Interleukin-6
INS	Idiopathic nephrotic syndrome
IRIDA	Iron-refractory iron deficiency anemia
LDL	Low density lipoproteins
LEAP	Liver-expressed antimicrobial peptide
LMW	Low molecular weight
LMWP	Low molecular weight protein
MCNS	Minimal change nephrotic syndrome
MCV	mean corpuscular volume
mHJV	Membrane isoform of Hemojuvelin

MMF	Mycophenolate mofetil
MPGN	Membranoproliferative glomerulonephritis
NMR	Nuclear Magnetic Resonance
NS	Nephrotic syndrome
PCR	Polymerase chain reaction
Pr/Cr ratio	Protein/creatinine ratio
RDW	Red cell distribution weadth
SBP	Systolic blood pressure
SDNS	Steroid dependent nephrotic syndrome
SLE	Systemic lupus erethromatosis
SMAD	Sons of against decapentaplegic mother
SNS	Secondary nephrotic syndrome
SRINS	Steroid resistant idiopathic nephrotic syndrome
SRNS	Steroid resistant nephrotic syndrome
SSNS	Steroid sensitive nephrotic syndrome
STAT-3	Signal transducer activator of transcription-3

TfR2	Transferrin receptor 2
TMPRSS6	Transmembrane serine protease 6
UTI	Urinary tract infection
VLDL	Very low density lipoproteins

LIST OF TABLES

Table No.	Title	Page
1	Etiology of nephrotic syndrome	5
2	HDL, high density lipoproteins; LDL, low density lipoproteins; VLDL, very low density lipoproteins	13
3	Hepcidin in pathogenesis of iron disorders.....	57
4	Comparison between cases and controls as regards to some demographic characteristics	64
5	Comparison between cases and controls as regards to arterial blood pressure	65
6	Comparison between cases and controls as regards to laboratory findings	66
7	Comparison between remission cases and controls as regards to demographic data	68
8	Comparison between remission cases and controls as regards to arterial blood pressure	68
9	Comparison between remission cases and controls as regards to laboratory data	69
10	Comparison between relapse cases and controls as regards to demographic data	71
11	Comparison between relapse cases and controls as regards to arterial blood pressure	71
12	Comparison between relapse cases and controls as regards to laboratory data	72
13	Comparison between remission and relapse cases as regards to demographic data	74

Table No.	Title	Page
14	Comparison between remission and relapse cases as regards to clinical data	75
15	Comparison between remission and relapse cases as regards to laboratory data.....	76
16	Comparison between remission and relapse cases as regards to renal biopsy.....	78
17	Comparison between remission and relapse in steroid responsive cases as regards to demographic data	78
18	Comparison between remission and relapse responsive cases as regards to clinical data	79
19	Comparison between remission and relapse responsive cases as regards to laboratory data	80
20	Comparison between remission and relapse resistant to steroid cases as regards to demographic characteristics.....	82
21	Comparison between remission and relapse resistant to steroid cases as regards to clinical data.....	83
22	Comparison between remission and relapse cases in steroid resistant cases as regards to laboratory data	84
23	Comparison between remission and relapse resistant cases as regards to renal biopsy	86
24	Correlation between serum Pro hepcidin and demographic data	87
25	Correlation between serum hepcidin and arterial blood pressure.....	88

Table No.	Title	Page
26	Correlation between serum hepcidin and laboratory data ...	91
27	Comparison between presence and absence of some complications as regards serum pro hepcidin in cases	99
28	Comparison between steroid responsive and resistant cases as regards to demographic data	101
29	Comparison between steroid responsive and resistant cases as regards to clinical data	102
30	Comparison between steroid responsive and resistant cases as regards to laboratory data	103
31	Renal biopsy in resistant cases.....	105

LIST OF FIGURES

Figure No.	Title	Page
1	Pathophysiology of nephrotic syndrome	9
2	Structure of hepcidin	35
3	Physiology of hepcidin	38
4	Positive regulation of hepcidin	41
5	BMP/ SMAD4 Pathway stimulation of hepcidin ..	42
6	Negative regulation of hepcidin	45
7	Hepcidin in chronic kidney disease	48
8	Effect of inflammation on hepcidin release	54
9	Comparison between cases and controls as regards to mean serum pro hepcidin	67
10	Comparison between remission cases and controls as regards to mean serum pro hepcidin	70
11	Comparison between relapse cases and controls as regards to mean serum pro hepcidin	73
12	Comparison between relapse cases and controls as regards to mean serum pro hepcidin	77
13	Comparison between remission and relapse responsive cases as regards to mean serum Pro hepcidin	81
14	Comparison between relapse cases and remission SRNS as regards to mean serum pro hepcidin.....	85

Figure No.	Title	Page
15	Correlation between serum pro hepcidin and duration of illness in cases	87
16	Correlation between serum pro hepcidin and SBP in all samples	89
17	correlation between serum Pro hepcidin and DBP in all samples	90
18	Correlation between serum pro hepcidin and Hb in all samples.....	92
19	Correlation between serum pro hepcidin and MCH in all samples	93
20	Correlation between serum pro hepcidin and MCV	94
21	Correlation between serum pro hepcidin and HCT in all samples	95
22	Correlation between serum pro hepcidin and serum iron in all samples	96
23	Correlation between serum pro hepcidin and P/C ratio in all samples.	97
24	Correlation between serum pro hepcidin and serum creatinine in all samples	98
25	Comparison between presence and absence complications as regards serum pro hepcidin in cases	99
26	Comparison between presence and absence of HTN as regards serum pro hepcidin in cases	100

Figure No.	Title	Page
27	Comparison between steroid responsive and resistant cases as regards to mean serum pro hepcidin	105

Introduction

Nephrotic syndrome (N.S.) is a clinical and biochemical state that may develop as a primary disease or during the course of several different renal diseases that damages the tiny blood-filtering units (glomeruli) in the kidneys (*Karnovsky and Ainsworth, 1976*). Characterized by proteinuria ($>1\text{g/m}^2/\text{day}$), hypoalbuminemia ($<2.5\text{ g/dL}$) and edema (*Frank et al., 2000*).

NS is a primarily pediatric disorder and is 15 times more common in children than adults, the incidence is 2-3/100,000 children per year, and the majority of affected children will have steroid-sensitive minimal change disease (*Vogt and Avner, 2007*). In Egypt, the annual incidence of NS ranged between 0.03-0.05% of children presented to the general Pediatric Nephrology Clinic, Ain Shams University (*Farid et al., 1997*).

Patients with NS have tendency to lose different types of proteins in urine including binding proteins as iron binding protein "transferrin" (*Keddis et al., 2007*). Transferrin is the most important glycoprotein for iron transport between sites of absorption and storage and use in the body, so decrease in serum transferrin in nephrotic patients leads to low plasma iron concentration (*Andrews, 1999*). In addition erythropoietin which is lost in urine, resulting in low plasma levels of erythropoietin. These factors combine to create iron resistant microcytic hypochromic anemia (*Keddis et al., 2007*).

Hepcidin is a 25-amino acid cysteine-rich peptide, present in human serum and urine. It is synthesized predominantly by hepatocytes as an 84-amino acid precursor protein and its mature form is released in circulation. This seems to be the "master regulator" of iron metabolism (*Kemna et al., 2008*).

Hepcidin acts by binding to ferroportin, which is located on the basolateral surface of gut enterocytes and the plasma membrane of reticuloendothelial cells, the only known cell iron exporter, inducing its internalization and subsequent degradation in the cytoplasm (*Ganz et al., 2008*).

In systemic level, hepcidin upregulation results in inhibition of iron absorption from intestinal enterocytes and iron recycling from macrophages. Hepcidin expression is up-regulated by Iron overload and inflammation, which increase hepcidin release whereas anemia and hypoxia suppress it (*Kemna et al., 2008*).